← Back to Search

Bronchodilator

Bronchodilator Therapy for Cystic Fibrosis

N/A

Waitlist Available

Led By Jordan A Guenette, PhD

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged 19 years or older

Currently non-smoking or a past smoking history of less than 20 pack-years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 min post-dose.

Awards & highlights

Study Summary

This trial is studying whether a bronchodilator drug can help improve shortness of breath, exercise performance, and breathing responses in adults with cystic fibrosis.

Who is the study for?

This trial is for adults with cystic fibrosis who experience difficulty breathing and limited exercise capacity. Eligible participants must have a specific range of lung function, be between the ages of 19 and older, have a body mass index from 16 to 30, and cannot currently smoke or have a heavy past smoking history. People with certain infections or other diseases affecting breathing, those needing supplemental oxygen, or with a history of organ transplantation can't join.Check my eligibility

What is being tested?

The study is testing whether Salbutamol—a bronchodilator medication that helps open up the airways in the lungs—can effectively reduce shortness of breath and improve exercise performance in CF patients compared to a placebo (a substance with no therapeutic effect).See study design

What are the potential side effects?

While not specified here, common side effects of bronchodilators like Salbutamol may include tremors, headache, fast heart rate, dizziness, throat irritation and muscle cramps.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 19 years old or older.

Select...

I am a non-smoker or have smoked less than 20 pack-years.

Select...

I have been diagnosed with cystic fibrosis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 min post-dose.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 min post-dose.

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 min post-dose. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Standardized dyspnea score at the highest equivalent submaximal exercise time achieved on both constant load exercise tests (i.e., iso-time).

Secondary outcome measures

Airways resistance on both constant load exercise tests.

Arterial oxygen saturation on both constant load exercise tests.

Exercise stress test

+11 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Salbutamol meter-dose inhalerActive Control1 Intervention

Inhalation of 400 μg salbutamol

Group II: Placebo meter-dose inhalerPlacebo Group1 Intervention

Inhalation of 400 μg placebo

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor

1,413 Previous Clinical Trials

2,466,941 Total Patients Enrolled

15 Trials studying Cystic Fibrosis

2,522 Patients Enrolled for Cystic Fibrosis

Jordan A Guenette, PhDPrincipal InvestigatorUniversity of British Columbia - Centre for Heart Lung Innovation

6 Previous Clinical Trials

166 Total Patients Enrolled

3 Trials studying Cystic Fibrosis

81 Patients Enrolled for Cystic Fibrosis

Media Library

Salbutamol (Bronchodilator) Clinical Trial Eligibility Overview. Trial Name: NCT03522831 — N/A

Cystic Fibrosis Research Study Groups: Placebo meter-dose inhaler, Salbutamol meter-dose inhaler

Cystic Fibrosis Clinical Trial 2023: Salbutamol Highlights & Side Effects. Trial Name: NCT03522831 — N/A

Salbutamol (Bronchodilator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03522831 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being enrolled in this experiment?

"This medical study is closed to new patients at this time, as the trial was originally posted on May 1st 2018 and last edited on May 17th 2022. If you are seeking trials for cystic fibrosis or Salbutamol Meter-Dose Inhaler treatments, there are 686 and 17 studies respectively that remain open for enrollment."

Answered by AI

Are there any vacancies left in this experiment?

"This study is not presently open to new participants. It was posted on May 1st 2018 and its most recent update occurred on the 17th of May 2022. For those wishing to find other studies, 686 trials for cystic fibrosis are currently accepting patients along with 17 involving Salbutamol meter-dose inhaler treatments."

Answered by AI

Could you provide information on prior research related to Salbutamol meter-dose inhaler?

"Currently, 17 clinical trials for the Salbutamol meter-dose inhaler are ongoing. None of them have progressed to Phase 3 yet. Ann Arbor, Michigan is home to most of these studies; however, there are also testing sites in 75 distinct locations."

Answered by AI

What medical condition is Salbutamol meter-dose inhaler commonly utilized to treat?

"Salbutamol meter-dose inhaler is an effective medication for exercise-induced bronchospasm, the use of bronchodilator agents, and respiratory tract infections."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

CF Bronchodilation

Jordan Guenette 2018. "CF Bronchodilation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03522831.

All > Fibrosis > Cystic Fibrosis